Apyx Medical (APYX) came out with a quarterly loss of $0.12 per share versus the Zacks Consensus Estimate of a loss of $0.13. This compares to loss of $0.19 per share a year ago. These figures are ...

Forward steps are being made in HNSCC, and the first patient with MDS has been treated with iadademstat/azacitidine.

It's probably worth relying on the recent Musselburgh winner King Ulanda in the handicap hurdle for conditional jockeys (2.50 ...

The FDA has granted PYX-201 fast track designation for treatment of recurrent or metastatic HNSCC after progression post-chemoimmunotherapy. PYX-201 received FDA fast track designation for use in ...

Phenom announced all sponsorship opportunities are sold out for its highly anticipated IAMPHENOM 2025 conference, the ...

A live webcast and replay of the fireside chat will be available on the Events & Presentations page in the Investor Relations section of Pyxis Oncology’s website, ir.pyxisoncology.com.

While foxes are opportunistic hunters they rarely target adult cats since cats can defend themselves with sharp claws and ...

The FDA has granted fast track designation to Pyxis oncology’s PYX-201 for the treatment of adults with R/M HNSCC.

NOTUS and the Allbritton Journalism Institute are partnering with a group of local newsrooms around the country to provide ...

PYX-201 has gained FDA fast track designation in recurrent or metastatic head and neck squamous cell carcinoma.

The US Food and Drug Administration (FDA) has granted fast track designation to Pyxis Oncology’s antibody-drug conjugate (ADC), PYX-201, to treat adults with recurrent or metastatic head and ...